ProfileGDS5678 / 1449923_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 51% 51% 49% 49% 52% 50% 50% 50% 50% 50% 49% 51% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2637751
GSM967853U87-EV human glioblastoma xenograft - Control 23.2125451
GSM967854U87-EV human glioblastoma xenograft - Control 33.2139751
GSM967855U87-EV human glioblastoma xenograft - Control 43.0937649
GSM967856U87-EV human glioblastoma xenograft - Control 53.1155449
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3604552
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2688450
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1934550
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1890350
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1887150
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2057850
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1422549
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2286951
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2054250